Swiss National Bank’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-120,700
| Closed | -$20.8M | – | 2778 |
|
|
2021
Q3 | $20.8M | Buy |
120,700
+600
| +0.5% | +$78.5K | 0.01% | 673 |
|
|
2021
Q2 | $15.1M | Buy |
120,100
+3,000
| +3% | +$378K | 0.01% | 798 |
|
|
2021
Q1 | $15.9M | Buy |
117,100
+2,000
| +2% | +$258K | 0.01% | 764 |
|
|
2020
Q4 | $14.7M | Buy |
115,100
+11,400
| +11% | +$1.34M | 0.01% | 749 |
|
|
2020
Q3 | $11.7M | Buy |
103,700
+2,500
| +2% | +$249K | 0.01% | 749 |
|
|
2020
Q2 | $9.64M | Buy |
101,200
+13,800
| +16% | +$1.33M | 0.01% | 789 |
|
|
2020
Q1 | $7.86M | Buy |
87,400
+1,400
| +2% | +$109K | 0.01% | 736 |
|
|
2019
Q4 | $4.56M | Buy |
86,000
+1,700
| +2% | +$77.5K | ﹤0.01% | 1216 |
|
|
2019
Q3 | $3.33M | Buy |
84,300
+2,500
| +3% | +$108K | ﹤0.01% | 1358 |
|
|
2019
Q2 | $3.36M | Buy |
81,800
+2,000
| +3% | +$82.8K | ﹤0.01% | 1372 |
|
|
2019
Q1 | $3.72M | Buy |
79,800
+14,700
| +23% | +$645K | ﹤0.01% | 1276 |
|
|
2018
Q4 | $2.83M | Buy |
65,100
+1,900
| +3% | +$94.9K | ﹤0.01% | 1339 |
|
|
2018
Q3 | $3.62M | Hold |
63,200
| – | – | ﹤0.01% | 1333 |
|
|
2018
Q2 | $3.07M | Sell |
63,200
-4,200
| -6% | -$153K | ﹤0.01% | 1427 |
|
|
2018
Q1 | $2.63M | Buy |
67,400
+5,100
| +8% | +$217K | ﹤0.01% | 1461 |
|
|
2017
Q4 | $2.64M | Hold |
62,300
| – | – | ﹤0.01% | 1465 |
|
|
2017
Q3 | $2.33M | Buy |
62,300
+12,000
| +24% | +$417K | ﹤0.01% | 1519 |
|
|
2017
Q2 | $1.53M | Buy |
50,300
+3,900
| +8% | +$113K | ﹤0.01% | 1762 |
|
|
2017
Q1 | $1.23M | Hold |
46,400
| – | – | ﹤0.01% | 1885 |
|
|
2016
Q4 | $1.18M | Buy |
46,400
+3,100
| +7% | +$98.2K | ﹤0.01% | 1923 |
|
|
2016
Q3 | $1.57M | Sell |
43,300
-1,500
| -3% | -$49.7K | ﹤0.01% | 1670 |
|
|
2016
Q2 | $1.52M | Buy |
44,800
+1,000
| +2% | +$32.5K | ﹤0.01% | 1703 |
|
|
2016
Q1 | $1.11M | Buy |
43,800
+18,100
| +70% | +$526K | ﹤0.01% | 1835 |
|
|
2015
Q4 | $1.25M | Hold |
25,700
| – | – | ﹤0.01% | 1654 |
|
|
2015
Q3 | $640K | Buy |
25,700
+3,700
| +17% | +$111K | ﹤0.01% | 2047 |
|
|
2015
Q2 | $696K | Buy |
22,000
+6,200
| +39% | +$200K | ﹤0.01% | 2030 |
|
|
2015
Q1 | $601K | Buy |
15,800
+700
| +5% | +$27.8K | ﹤0.01% | 2071 |
|
|
2014
Q4 | $588K | Hold |
15,100
| – | – | ﹤0.01% | 2080 |
|
|
2014
Q3 | $457K | Hold |
15,100
| – | – | ﹤0.01% | 2157 |
|
|
2014
Q2 | $513K | Buy |
+15,100
| New | +$505K | ﹤0.01% | 2158 |
|
Swiss National Bank's XLRN Position: Q4 2021 in Review
Swiss National Bank sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 120,700 shares — an estimated $20.8M sold.
Swiss National Bank first reported a position in XLRN in Q2 2014 and held it in 30 quarters. The position peaked at $20.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Swiss National Bank reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Swiss National Bank sold 120,700 Acceleron Pharma shares in Q4 2021, an estimated $20.8M.
- Swiss National Bank first reported a position in Acceleron Pharma in Q2 2014 and held it in 30 quarters.
- Swiss National Bank's Acceleron Pharma position peaked at $20.8M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.